These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 31385441)

  • 61. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
    Burmester GR; Curtis JR; Yun H; FitzGerald O; Winthrop KL; Azevedo VF; Rigby WFC; Kanik KS; Wang C; Biswas P; Jones T; Palmetto N; Hendrikx T; Menon S; Rojo R
    Drug Saf; 2020 Apr; 43(4):379-392. PubMed ID: 32006348
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
    Sonomoto K; Yamaoka K; Kubo S; Hirata S; Fukuyo S; Maeshima K; Suzuki K; Saito K; Tanaka Y
    Rheumatology (Oxford); 2014 May; 53(5):914-8. PubMed ID: 24441153
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program.
    Mariette X; Chen C; Biswas P; Kwok K; Boy MG
    Arthritis Care Res (Hoboken); 2018 May; 70(5):685-694. PubMed ID: 28941219
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
    Castañeda OM; Romero FJ; Salinas A; Citera G; Mysler E; Rillo O; Radominski SC; Cardiel MH; Jaller JJ; Alvarez-Moreno C; Ponce de Leon D; Castelli G; García EG; Kwok K; Rojo R
    J Clin Rheumatol; 2017 Jun; 23(4):193-199. PubMed ID: 28145906
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
    Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
    Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
    Winthrop KL; Park SH; Gul A; Cardiel MH; Gomez-Reino JJ; Tanaka Y; Kwok K; Lukic T; Mortensen E; Ponce de Leon D; Riese R; Valdez H
    Ann Rheum Dis; 2016 Jun; 75(6):1133-8. PubMed ID: 26318385
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
    Orsolini G; Bertoldi I; Rossini M
    Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
    Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Thirunavukkarasu K; DeMasi R; Geier J; Kwok K; Wang L; Riese R; Wollenhaupt J
    Ann Rheum Dis; 2017 Jul; 76(7):1253-1262. PubMed ID: 28143815
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Qiu C; Zhao X; She L; Shi Z; Deng Z; Tan L; Tu X; Jiang S; Tang B
    Lipids Health Dis; 2019 Feb; 18(1):54. PubMed ID: 30777075
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.
    Wongcharoen W; Sutthiwutthichai S; Gunaparn S; Phrommintikul A
    BMC Cardiovasc Disord; 2017 Jan; 17(1):10. PubMed ID: 28056802
    [TBL] [Abstract][Full Text] [Related]  

  • 73. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
    Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
    Panaccione R; Isaacs JD; Chen LA; Wang W; Marren A; Kwok K; Wang L; Chan G; Su C
    Dig Dis Sci; 2021 Aug; 66(8):2732-2743. PubMed ID: 32816215
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis.
    Wolk R; Armstrong EJ; Hansen PR; Thiers B; Lan S; Tallman AM; Kaur M; Tatulych S
    J Clin Lipidol; 2017; 11(5):1243-1256. PubMed ID: 28751001
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis.
    Iwamoto N; Tsuji S; Takatani A; Shimizu T; Fukui S; Umeda M; Nishino A; Horai Y; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Hirai Y; Tamai M; Nakamura H; Terada K; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    PLoS One; 2017; 12(5):e0177057. PubMed ID: 28472115
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tofacitinib for treatment of rheumatoid arthritis.
    Rakieh C; Conaghan PG
    Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study.
    Dai W; Zhang Z; Zhao S
    Lipids Health Dis; 2018 Dec; 17(1):273. PubMed ID: 30509306
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
    Strand V; Ahadieh S; French J; Geier J; Krishnaswami S; Menon S; Checchio T; Tensfeldt TG; Hoffman E; Riese R; Boy M; Gómez-Reino JJ
    Arthritis Res Ther; 2015 Dec; 17():362. PubMed ID: 26669566
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.